Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Recurrent Chronic Lymphocytic Leukemia
- B-cell Prolymphocytic Leukemia
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Mantle Cell Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Non Hodgkin Lymphoma
- Refractory Small Lymphocytic Lymphoma
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Diffuse Large B Cell Lymphoma
- Richter Syndrome
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of pevonedistat administered in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). SECONDARY OBJECTIVES: I. Overall response rate (ORR) will be determined...
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerability of pevonedistat administered in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). SECONDARY OBJECTIVES: I. Overall response rate (ORR) will be determined based on the proportion of study participants who achieve complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR) or nodular partial response (nPR) assessed after completion of therapy. II. Event-free survival (EFS), defined as the interval between the date of first study treatment and the date of objective signs of disease recurrence, subsequent anti-leukemic therapy, or death, whichever is first reported. OUTLINE: This is a dose-escalation study of pevonedistat. Participants receive pevonedistat intravenously (IV) over 1 hour on days 1, 3, and 5, and ibrutinib orally (PO) daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants will be followed up for every 3 months
Tracking Information
- NCT #
- NCT03479268
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Alexey Danilov City of Hope Medical Center